Unicycive Therapeutics, Inc.
UNCY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001766140
No open-market purchases or sales by Unicycive Therapeutics, Inc. insiders were filed in the last 90 days; 79 institutions reported holding it in 13F filings for Q2 2026, worth $54.6M in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Unicycive Therapeutics, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 0 | 10 | +10 |
| Shares | 0 | 1.07M | +1.07M |
| Value | $0 | $3.02M | +$3.02M |
New holders (10)
Institutions that held Unicycive Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Nantahala Capital Management, LLC | 700,000 | $1.98M | 0.12% |
| Board of Trustees of The Leland Stanford Junior University | 247,583 | $700.0K | 0.05% |
| Geode Capital Management, LLC | 26,109 | $73.0K | 0.00% |
| Two Sigma Investments, LP | 25,551 | $72.0K | 0.00% |
| Sanders Morris Harris LLC | 20,000 | $57.0K | 0.01% |
| Frontier Wealth Management LLC | 18,838 | $53.0K | 0.00% |
| Tandem Capital Management Corp | 15,500 | $44.0K | 0.03% |
| BlackRock Inc. | 11,443 | $33.0K | 0.00% |
| UBS Group AG | 621 | $2.00K | 0.00% |
| Wells Fargo & Company | 32 | $0 | 0.00% |
Sold out (0)
Institutions that held Unicycive Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
None.